Quinidine

Antiarrhythmic — CARDIOVASCULAR SYSTEM

Key facts

Quinidine is an ofp drug in the Antiarrhythmic class catalogued in DrugCentral. It was first approved by the FDA in 1950. Its mechanism of action is classified as Cytochrome P450 2D6 Inhibitors. DrugCentral lists 23 molecular targets, including CHRM2, CYP2D6 and KCNH2. Recorded indications include Atrial fibrillation, Cardioversion of Atrial Fibrillation, Life-Threatening Ventricular Tachycardia and Malaria.

• Approval status: ofp (first approved 1950 by the FDA).
• Drug class: Antiarrhythmic; Cytochrome P450 2D6 Inhibitor.
• Mechanism of action: Cytochrome P450 2D6 Inhibitors.
• Molecular targets: CHRM2, CYP2D6, KCNH2 and BCHE (23 listed in DrugCentral).
• Indications: Atrial fibrillation, Cardioversion of Atrial Fibrillation, Life-Threatening Ventricular Tachycardia, Malaria and Pseudobulbar affect.
• ATC code: C01BA01 (Antiarrhythmics, class Ia).
• Molecular formula: C20H24N2O2; molecular weight 324.42 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (5)

• Atrial fibrillation
• Cardioversion of Atrial Fibrillation
• Life-Threatening Ventricular Tachycardia
• Malaria
• Pseudobulbar affect

Contraindications (25)

• Anemia due to enzyme deficiency
• Bradycardia
• Chronic heart failure
• Complete atrioventricular block
• Congenital long QT syndrome
• Digitalis Toxicity with AV Conduction Defects
• Disease of liver
• Esophageal dysmotility
• Hypokalemia
• Hypomagnesemia
• Kidney disease
• Left bundle branch block
• Left heart failure
• Left ventricular hypertrophy
• Low blood pressure
• Myasthenia gravis
• Non-specific intraventricular conduction delay
• Partial atrioventricular block
• Poisoning by digitalis glycoside
• Poisoning by quinidine
• Prolonged QT interval
• Psoriasis
• Pulmonary emphysema
• Thrombocytopenic disorder
• Torsades de pointes

Mechanism & targets

• Mechanism of action (MoA): Cytochrome P450 2D6 Inhibitors
• Established pharmacologic class: Antiarrhythmic; Cytochrome P450 2D6 Inhibitor

Molecular targets (23)

Target	Gene	Action	Activity
Muscarinic acetylcholine receptor M2	CHRM2	unknown	Ki 8.12
Cytochrome P450 2D6	CYP2D6	inhibitor	Ki 7.92
Potassium voltage-gated channel subfamily H member 2	KCNH2	unknown	IC50 6.49
Cholinesterase	BCHE	unknown	IC50 5.91
Potassium voltage-gated channel subfamily H member 1	KCNH1	blocker	IC50 5.80
Potassium voltage-gated channel subfamily D member 2	Kcnd2	unknown	IC50 5.66
Multidrug resistance protein 1	ABCB1	unknown	Ki 5.59
Sodium channel alpha subunits; brain (Types I, II, III)	SCN1A|SCN2A|SCN3A	blocker	IC50 5.49
Potassium voltage-gated channel subfamily A member 5	KCNA5	blocker	Kd 5.20
Sodium channel protein type 5 subunit alpha	SCN5A	blocker	IC50 5.16
Cholinesterase	BCHE	unknown	IC50 5.13
Sodium channel protein type 5 subunit alpha	Scn5a	blocker	IC50 5.00
Multidrug and toxin extrusion protein 1	SLC47A1	unknown	IC50 4.95
Potassium voltage-gated channel subfamily A member 7	KCNA7	blocker	Kd 4.80
Potassium channel subfamily T member 1	KCNT1	unknown	IC50 4.80
Equilibrative nucleoside transporter 4	SLC29A4	inhibitor	Ki 4.60
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4	HCN4	unknown	IC50 4.11
Solute carrier family 22 member 2	SLC22A2	unknown	IC50 4.06
Potassium channel subfamily T member 1	Kcnt1	blocker	IC50 4.00
Sodium channel subunit beta-4	SCN4B	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1950-07-12	FDA	—	LILLY

ATC classification

ATC code	Therapeutic hierarchy
C01BA01	CARDIOVASCULAR SYSTEM › CARDIAC THERAPY › ANTIARRHYTHMICS, CLASS I AND III › Antiarrhythmics, class Ia
C01BA51	CARDIOVASCULAR SYSTEM › CARDIAC THERAPY › ANTIARRHYTHMICS, CLASS I AND III › Antiarrhythmics, class Ia
C01BA71	CARDIOVASCULAR SYSTEM › CARDIAC THERAPY › ANTIARRHYTHMICS, CLASS I AND III › Antiarrhythmics, class Ia

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: CYP2D6

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Electrocardiogram QT prolonged	96.9
Gliosis	94.2
Polyserositis	90.4
Premature menopause	87.3
Ovarian failure	85.1
Pouchitis	83.9
Somatic symptom disorder	75.7
Antiphospholipid syndrome	74.5
Venous thrombosis limb	65.3
Drug ineffective	63.6
Multiple-drug resistance	54.8
Cardiac tamponade	54.1

Chemical structure

• Molecular formula: C₂₀H₂₄N₂O₂
• Molecular weight: 324.42 g/mol
• CAS number: —
• InChIKey: LOUPRKONTZGTKE-LHHVKLHASA-N
• PubChem CID: 441074

COC1=CC=C2N=CC=C([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)C2=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Quinidine used for?

DrugCentral lists the following indications for Quinidine: Atrial fibrillation, Cardioversion of Atrial Fibrillation, Life-Threatening Ventricular Tachycardia, Malaria and Pseudobulbar affect.

How does Quinidine work?

Quinidine is classified as Cytochrome P450 2D6 Inhibitors; its molecular targets in DrugCentral include CHRM2, CYP2D6 (inhibitor), KCNH2 and BCHE.

When was Quinidine first approved?

Quinidine was first approved by the FDA in 1950.

What drug class does Quinidine belong to?

Quinidine is in the Antiarrhythmic class.

What is the chemical formula of Quinidine?

Quinidine has the molecular formula C20H24N2O2 and a molecular weight of 324.42 g/mol.

Sources

• DrugCentral drug card 2346 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200437 — compound record and bioactivity
• PubChem CID 441074 — chemical identifiers
• DrugBank DB00908 — drug record
• FDA UNII ITX08688JL — substance identity
• DailyMed: FDA labels for Quinidine — current prescribing information (label search)
• UniProt P08172 (CHRM2) — target protein
• UniProt P10635 (CYP2D6) — target protein
• UniProt Q12809 (KCNH2) — target protein
• UniProt P06276 (BCHE) — target protein
• UniProt O95259 (KCNH1) — target protein
• UniProt P08183 (ABCB1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.